The Food & Drug Administration is moving forward with a pilot program that streamlines the review process for supplemental applications for oncology treatments that meet specific criteria.
After a successful review of Genentech Inc.’s Avastin sBLA for cervical cancer, FDA says a second application has gone through the abbreviated process. FDA declined to name the application,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?